International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 2 (March-April 2025) Submit your research before last 3 days of April to publish your research paper in the issue of March-April.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 2
March-April 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

GLP Agonist and Weight Loss: A Systemic Review on GLP-1 Agonist and Its Effect on the Pancreas for Nondiabetic Patients of African Descent

Author(s) Uchechukwu Chiadikobi, Tamunoiyalla Ordor
Country United States
Abstract The GLP-1 receptor agonists represent an innovative pharmacological solution for weight reduction in people who do not have diabetes. These medication agents showed their initial development in glycemic control of Type 2 diabetes patients. They later proved their effectiveness in producing substantial weight loss through simultaneous appetite regulation, gastric emptying, and energy balance systems. Scientists are researching how these medications affect pancreatic function in patients who do not have diabetes and specifically in African descent individuals. The survey examines GLP-1 receptor agonist effects on pancreatic health by analyzing their outcomes and safety for nondiabetic African descent patients while examining genetic and metabolic alongside environmental influences.
Recent research indicates that semaglutide and liraglutide, alongside other GLP-1 receptor agonists, trigger pancreatic cell effects, including beta-cell growth and better insulin release capabilities. Research exists about the risk of pancreatic hypertrophy, where the pancreas increases in size, possible pancreatitis development, and cellular alteration persistence. Metabolic characteristics and genetic determinants found in African populations affect how effective these medications become and how they interact with patient health. Research-based evidence shows that African populations require individual assessment of GLP-1 receptor agonists because their beta-cell function, insulin sensitivity, and lipid regulation differ from other ethnicities. When healthcare professionals understand how different demographic groups respond to treatment, patients benefit from safe medication therapy.
The review brings together existing research about GLP-1 receptor agonists and their weight loss outcomes and effects on pancreas function in nondiabetic people of African descent. It fully understands these agents' potential advantages and examines clinical trial data, observational studies, and mechanistic reports. Researchers will use the research findings to establish customized medical plans for healthcare providers who need to weigh the weight management advantages against pancreatic implications, which mainly affect nondiabetic Africans.
Keywords GLP-1 Receptor Agonists, Weight Loss, Pancreas, Nondiabetic, African Descent, Semaglutide, Liraglutide, Metabolic Health, Obesity Management, Insulin Secretion, Beta-Cell Function, Pancreatic Hypertrophy, Pancreatitis Risk, Glucose Metabolism, Genetic Predisposition, Lipid Metabolism, Appetite Regulation, Gastric Emptying, Energy Balance, Clinical Trials, Observational Studies, Pharmacokinetics, Ethnic Variations, Personalized Medicine, Endocrinology, Hormone Regulation, Metabolic Syndrome, Cardiovascular Health, Therapeutic Strategies, Safety Profile, Diabetes Prevention
Field Medical / Pharmacy
Published In Volume 7, Issue 2, March-April 2025
Published On 2025-03-20
DOI https://doi.org/10.36948/ijfmr.2025.v07i02.39726
Short DOI https://doi.org/g89vtb
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 2Cover Page Vol 7 Isu 1Cover Page Vol 6 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com